(Q36343529)

13 August 2017

1 reference

title

Bone marrow angiogenesis in multiple myeloma (English)

1 reference

13 August 2017

1 reference

1 reference

Vacca A

1

1 reference

13 August 2017

Ribatti D

series ordinal

2

1 reference

13 August 2017

publication date

1 February 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

20

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

193-199

1 reference

Bone marrow angiogenesis and progression in multiple myeloma.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Angiogenesis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Angiogenesis in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Do human myeloma cells directly produce basic FGF?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Identification of genes modulated in multiple myeloma using genetically identical twin samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Bone marrow angiogenesis in patients with active multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

alpha(v)beta(3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Myeloma cells (5TMM) and their interactions with the marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Endothelial cells in the bone marrow of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Circulating endothelial progenitor cells in multiple myeloma: implications and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Multiple myeloma: evolving genetic events and host interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Mast cell contribution to angiogenesis related to tumour progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Thalidomide as anti-inflammatory therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Therapeutic renaissance of thalidomide in the treatment of haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Expression of VEGF and its receptors by myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Prognostic value of angiogenesis in solitary bone plasmacytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical–biological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

Increased vascularization in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

Osteopontin, angiogenesis and multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404067

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404067

1 reference

13 August 2017

1 reference